Tempus AI Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Tempus AI wird ein jährliches Gewinn- und Umsatzwachstum von 43.6% bzw. 17.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 43.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.8% betragen.
Wichtige Informationen
43.6%
Wachstumsrate der Gewinne
43.78%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 18.6% |
| Wachstumsrate der Einnahmen | 17.5% |
| Zukünftige Eigenkapitalrendite | 19.84% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 11 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Sep 03
TEM: MRD And Oncology Data Platforms Balance Oncology Demand And Execution Risk
Tempus AI's updated analyst price target has moved higher to reflect a revised fair value estimate of $66.73. Analysts highlight improving modeled profit margins, a slightly lower discount rate, and fresh research pointing to the value of its precision oncology platform and data driven applications.
Narrative-Update • Aug 28
Tempus AI: The Data Flywheel Is Starting to Work
My original thesis on Tempus AI was that this isn’t simply another AI software company. It’s building a healthcare data platform where diagnostics generate data, that data improves its AI products, and better products attract more customers and generate even more data.Seeking Alpha • Aug 18
Tempus AI: The Data Flywheel Has Started Spinning
Summary Tempus AI reported its first GAAP profit, accelerated data business growth, and raised 2026 revenue guidance to $1.595B–$1.605B (+25% Y/Y). Operating leverage from oncology volume and a mix shift to high-margin Data & Apps (72%-75% GM) drove profitability improvement and narrowed cash outflows. FDA approval for xT CDx and higher xF liquid biopsy ASPs is expected to add ~$400M incremental revenue by 2028, with the Personalis acquisition targeting MRD leadership. At 6.1x FY2026E EV/sales, valuation remains rich, but TEM’s defensive data assets and high-growth execution support a maintained 'Buy' rating. Read the full article on Seeking AlphaNarrative-Update • Aug 15
TEM: MRD And Oncology Data Platforms Will Drive Future Oncology Demand
Analysts have trimmed the average price target on Tempus AI to about $62.64 from $66.53, reflecting updated views on slower progress toward profitability, a higher implied discount rate, and the near term financial impact of the pending Personalis acquisition, even as some remain encouraged by MRD growth and long term oncology data opportunities. Analyst Commentary Recent research updates on Tempus AI give you a mixed picture.
Narrative-Update • Aug 01
TEM: Personalis Acquisition Risk May Limit Early Healthcare AI Upside
Tempus AI's updated Analyst Price Target framework shifts fair value to $35.65, reflecting analysts' incorporation of the Personalis acquisition terms, updated diagnostics group targets, and more cautious assumptions on discount rate and future P/E, even as they highlight Tempus AI's role in precision oncology and healthcare AI. Analyst Commentary Recent research on Tempus AI highlights a mix of enthusiasm around its positioning in healthcare AI and precision oncology, alongside a clear line of caution on valuation, execution around acquisitions, and the pace of growth needed to justify current expectations.Narrative-Update • Jul 11
TEM: Early Healthcare AI Theme And Profit Concerns May Restrain Upside
Tempus AI's analyst fair value estimate has shifted from about $58.00 to $37.83 as analysts factor in slightly softer revenue growth, more modest long term profit margin expectations, and a lower future P/E multiple, while still acknowledging the company's differentiated oncology data platform and early position in healthcare AI. Analyst Commentary Recent research on Tempus AI points to a split view.
Narrative-Update • Jun 27
TEM: FDA Approvals And Data Platform Progress Will Drive Future Upside
The analyst fair value estimate for Tempus AI has shifted from about $105.00 to roughly $95.45, as analysts recalibrate assumptions on revenue growth, profit margins, discount rate, and future P/E in light of recent mixed research that praises the company's differentiated data platform while questioning the clarity and timing of long term monetization. Analyst Commentary Recent Street research on Tempus AI points to a mixed but active debate, with several bullish analysts highlighting strengths in the company’s data platform and potential for execution on its long term roadmap.Analyseartikel • Jun 19
Tempus AI (TEM) Stock Could Be 22.9% Undervalued After ECG AF Validation
Tempus AI (TEM) is back in focus after publishing a multi site validation of its FDA cleared ECG AF software, which predicts one year atrial fibrillation or flutter risk in older adults without prior AF. See our latest analysis for Tempus AI. Tempus AI’s shares have picked up momentum recently, with a 1 month share price return of 10.81% and a 7 day gain of 6.32%. However, the year to date share price return is still down 18.47% and the 1 year total shareholder return has declined 25.57%...Narrative-Update • Jun 13
TEM: FDA Progress And Data Platforms Will Drive Future Oncology Demand
Tempus AI's analyst price targets have shifted lower to around $66.53, reflecting a mix of downward revisions and more cautious views on long term monetization from several firms, even as others acknowledge the company's differentiated data offering. Analyst Commentary Recent research paints a mixed picture around Tempus AI, with views split on how quickly the company can translate its differentiated data assets into predictable cash flows and what that should mean for valuation.Neues Narrative • Jun 09
An Overlooked AI Play That’s Quietly Building a Healthcare Data Empire
Tempus AI isn't simply an AI software business (not another ChatBot). It's building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.Narrative-Update • May 30
TEM: FDA Approvals And Partnerships Will Support Future Oncology Data Demand
Narrative Update The average analyst price target for Tempus AI has moved lower by several dollars to reflect a mix of reduced targets from H.C. Wainwright, BTIG, Baird, Guggenheim, and Morgan Stanley, partially offset by modest upward revisions and an upgrade from TD Cowen and TD Securities. Analysts are incorporating recent results, updated models, and ongoing partnership activity into their assessments.Narrative-Update • May 13
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Upside
Tempus AI's analyst price target is now $67.20, down from $72.40, as analysts adjust their models to reflect more moderate revenue growth assumptions and mixed recent price target revisions across the Street. Analyst Commentary Recent research on Tempus AI shows a mix of optimism and caution as analysts update their models, adjust price targets, and refine views following Q4 results and new coverage initiations.Narrative-Update • Apr 28
TEM: Data Partnerships And Backlog Will Support Future Oncology Data Monetization
Analysts have slightly reduced the blended price target on Tempus AI to $72.40. This reflects updated models around revenue growth, profit margins and P/E assumptions after a mix of target cuts and increases across recent research, including responses to Q4 results and ongoing partnership momentum.Narrative-Update • Apr 13
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Leadership
Narrative Update on Tempus AI The updated analyst price target for Tempus AI moves to $72.73 from $77.93, as analysts factor in slightly higher discount rates and a lower future P/E multiple. They still point to ongoing partnerships and data backlog as key supports for the long term story.Narrative-Update • Mar 26
TEM: Data Partnerships And Backlog Will Drive Future Precision Oncology Execution
Analysts report a modestly adjusted fair value estimate of $77.93 per share for Tempus AI, reflecting mixed price target revisions that weigh the impact of new partnerships and data backlog strength against updated post Q4 models and views on visibility in parts of the business. Analyst Commentary Recent Street research on Tempus AI reflects a split view, with some focusing on growth potential in precision medicine and data, and others emphasizing execution risks and visibility in parts of the business.Narrative-Update • Mar 11
TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Upside
Our updated view trims Tempus AI's implied fair value from about $86.71 to $77.93 per share, reflecting analysts' mixed price target revisions after Q4. Some highlight expanding pharma and academic partnerships and a large data backlog, while others factor in model updates, valuation resets, and questions around data upside and Ambry.Neues Narrative • Mar 04
Heavy AI Infrastructure And Rising Costs Will Pressure Data Economics Yet Eventually Support Upside
Catalysts About Tempus AI Tempus AI provides AI driven molecular diagnostics and data products to support clinical decision making and drug development. What are the underlying business or industry changes driving this perspective?Narrative-Update • Feb 24
TEM: Precision Oncology And AI Biomarkers Will Support Future Upside Potential
Narrative update on Tempus AI The updated analyst price target for Tempus AI has edged down by about $1 to reflect slightly lower fair value and profit margin assumptions, even as analysts highlight the company's role in precision oncology diagnostics and AI-enabled healthcare data services as a key factor in its long term revenue growth outlook. Analyst Commentary Recent research coverage on Tempus AI highlights both enthusiasm for its role in precision oncology and AI driven healthcare data, and a set of execution and valuation questions that investors are watching closely.Neues Narrative • Feb 18
Genomics And AI Data Licensing Will Transform Long Term Oncology Outcomes
Catalysts About Tempus AI Tempus AI operates a genomics and data platform focused on Oncology and related clinical insights. What are the underlying business or industry changes driving this perspective?Narrative-Update • Feb 10
TEM: AI Biomarker Advancements In Oncology Will Drive Future Returns
Analysts have nudged their price target on Tempus AI higher to about US$87.92, citing slightly stronger modeled revenue growth, profit margins, and a marginally lower future P/E assumption in their updated forecasts. What's in the News Tempus reported new clinical validation data for its Immune Profile Score test, indicating that the algorithmic biomarker more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than several conventional biomarkers across multiple metastatic solid tumor cohorts.Narrative-Update • Jan 26
TEM: Oncology Data Collaborations And AI Pathology Will Drive Future Returns
Analysts have kept their fair value estimate for Tempus AI steady at about US$87.92 per share, with only very small tweaks to inputs like discount rate, revenue growth, profit margins and future P/E assumptions supporting an unchanged overall target. What's in the News Tempus AI launched Paige Predict, a suite of AI pathology tools that analyze H&E whole slide images to help predict the likelihood of 123 biomarkers and oncogenic pathways across 16 cancer types, with results delivered alongside clinical reports to physicians (Product-Related Announcements).Narrative-Update • Jan 12
TEM: Oncology Data Collaborations Will Drive Future Returns Despite Slightly Higher Risk
Analysts have trimmed their fair value estimate for Tempus AI by about US$1.00, reflecting slightly higher discount rate assumptions as well as marginally adjusted revenue growth, profit margin, and future P/E inputs. What's in the News Tempus AI plans to present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, focusing on multimodal real world data, risk stratification for CDK4/6 inhibitor plus endocrine therapy, and tumor microenvironment signatures in hormone receptor positive, HER2 negative metastatic breast cancer (Key Developments).Narrative-Update • Dec 25
TEM: Future Oncology Data Partnerships Will Drive Profits Despite Modestly Higher Risk
Analysts have modestly reduced their price target on Tempus AI by approximately 3 dollars, reflecting slightly higher perceived risk and marginally slower long term growth expectations, partly offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Tempus AI will present ten research abstracts at the 2025 San Antonio Breast Cancer Symposium, showcasing multimodal real world data approaches to better stratify metastatic breast cancer patients and identify responders to CDK4/6 inhibitors (Key Developments).Narrative-Update • Dec 11
TEM: Future Profit Margins Will Expand As Federal Oncology Program Catalysts Mature
Narrative Update on Tempus AI Analyst Price Target Analysts have slightly raised their price target on Tempus AI to approximately 91 dollars and 42 cents from 91 dollars, citing a marginally lower perceived risk profile and stable long term growth and profitability assumptions. What's in the News Tempus received FDA 510(k) clearance for its RNA based xR IVD sequencing assay, expanding its toolkit for drug development partners and strengthening its position as a comprehensive precision oncology platform (FDA filing).Narrative-Update • Nov 26
TEM: Future Profit Margins Will Expand With AI-Powered Clinical Partnerships
Analysts have revised Tempus AI's price target upwards from $87.17 to $91.00, citing improved profit margin projections and a significantly lower anticipated future price-to-earnings ratio. What's in the News Tempus AI and the Institute for Follicular Lymphoma Innovation (IFLI) launched their first collaborative research study with a non-profit foundation to create a comprehensive, multi-omic dataset for follicular lymphoma.Narrative-Update • Nov 09
TEM: Revenue Will Accelerate With New Real-World Data Partnership
Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation. What's in the News Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).Narrative-Update • Oct 26
Advances In Precision Medicine And AI Will Reshape Cancer Care Futures
Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections. What's in the News Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 2,362 | -117 | 106 | 246 | 13 |
| 12/31/2027 | 1,968 | -236 | 25 | 79 | 21 |
| 12/31/2026 | 1,596 | -246 | -12 | -8 | 21 |
| 6/30/2026 | 1,432 | -254 | -273 | -237 | N/A |
| 3/31/2026 | 1,364 | -303 | -220 | -186 | N/A |
| 12/31/2025 | 1,272 | -245 | -245 | -218 | N/A |
| 9/30/2025 | 1,105 | -203 | -249 | -221 | N/A |
| 6/30/2025 | 952 | -199 | -73 | -52 | N/A |
| 3/31/2025 | 803 | -720 | -213 | -193 | N/A |
| 12/31/2024 | 693 | -745 | -211 | -189 | N/A |
| 9/30/2024 | 640 | -801 | -207 | -190 | N/A |
| 6/30/2024 | 596 | -790 | -325 | -292 | N/A |
| 3/31/2024 | 562 | -293 | -284 | -249 | N/A |
| 12/31/2023 | 532 | -254 | -249 | -214 | N/A |
| 9/30/2023 | 485 | -276 | -266 | -233 | N/A |
| 12/31/2022 | 321 | -334 | -187 | -168 | N/A |
| 9/30/2022 | 293 | -325 | -192 | -173 | N/A |
| 12/31/2021 | 258 | -298 | -224 | -212 | N/A |
| 9/30/2021 | 285 | -296 | -205 | -193 | N/A |
| 6/30/2021 | 284 | -286 | -199 | -188 | N/A |
| 3/31/2021 | 236 | -270 | -209 | -198 | N/A |
| 12/31/2020 | 188 | -254 | -220 | -207 | N/A |
| 12/31/2019 | 62 | -148 | N/A | -117 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: TEM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.7%).
Ertrag vs. Markt: TEM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: TEM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: TEMDie Einnahmen des Unternehmens (17.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (13.4% pro Jahr).
Hohe Wachstumseinnahmen: TEMDie Einnahmen des Unternehmens (17.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: TEMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.8%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/14 23:18 |
| Aktienkurs zum Tagesende | 2026/09/14 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Tempus AI, Inc. wird von 28 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Michael Ryskin | BofA Global Research |